Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Argenx Se (ARGX) and AnaptysBio (ANAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Microbot Medical (MBOT)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Microbot Medical, with a price target of $12.00. The company’s shares closed last Tuesday at $2.88.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 25.5% and a 57.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

Microbot Medical has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See today’s best-performing stocks on TipRanks >>

Argenx Se (ARGX)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Argenx Se, with a price target of $1057.00. The company’s shares closed last Tuesday at $812.95.

According to TipRanks.com, Archila is a 5-star analyst with an average return of 13.4% and a 53.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., Zentalis Pharmaceuticals, and Apellis Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $846.05 average price target, a 5.9% upside from current levels. In a report issued on October 2, Goldman Sachs also maintained a Buy rating on the stock with a $916.00 price target.

AnaptysBio (ANAB)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on AnaptysBio today and set a price target of $59.00. The company’s shares closed last Tuesday at $31.85.

According to TipRanks.com, Bodnar is a 3-star analyst with an average return of 3.5% and a 37.5% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Acrivon Therapeutics, Inc., and Olema Pharmaceuticals. ;'>

Currently, the analyst consensus on AnaptysBio is a Strong Buy with an average price target of $58.25, which is a 77.1% upside from current levels. In a report issued on October 13, Barclays also initiated coverage with a Buy rating on the stock with a $78.00 price target.

Read More on MBOT:

Disclaimer & DisclosureReport an Issue

• Microbot Medical Partners for LIBERTY System Launch
• Microbot Medical partners with 3PL company to commercialize LIBERTY System
• Microbot Medical files to sell 900,153 shares of common stock for holders
• Microbot Medical files to sell 14.69M shares of common stock for holders
• Microbot Medical Completes Final Closing of Investment Options